The Meningitis/Encephalitis Panel (MEP) is a sensitive and specific Food and Drug Administration-approved molecular diagnostic test for the 14 most common infectious etiologies of meningoencephalitis. Using a before-after controlled study design, MEP reduced length of hospital stay by 1.5 days, and this effect was mediated by the reduced time to final microbiology reporting.
No takes yet. Share an insight, caveat, or question.
Giulio DiDiodato (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: